MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1060028019828954

Медицинская библиотека · The Annals of pharmacotherapy · 2019

Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.

Doughty Bennett, Morgenson Daralyn, Brooks Tracy

СтатьяОбзорПеревод в очереди

Аннотация

OBJECTIVE

To review the pharmacology, efficacy, and safety of lofexidine for the treatment of opioid withdrawal secondary to the recent Food and Drug Administration (FDA) approval.

DATA SOURCES: A literature search using PubMed was conducted (inception to December 2018) using the terms lofexidine, opioid, opiate, and withdrawal. References from retrieved articles and the prescribing information were reviewed for any additional material.

STUDY SELECTION/DATA EXTRACTION: The literature search was limited to human studies published in English that pertained to human pharmacology, pharmacokinetics, pharmacodynamics, dosing, efficacy, and safety regarding opioid withdrawal. Phase I, II, and III studies of lofexidine for opioid withdrawal were reviewed for inclusion.

DATA SYNTHESIS: Lofexidine is newly FDA approved in the United States for the treatment of opioid withdrawal symptoms in adults. Several randomized controlled trials and a Cochrane review noted the effectiveness of lofexidine versus placebo for this indication. The efficacy of lofexidine has also been shown to be comparable to that of other indicated first- and second-line pharmacological agents. Relevance to Patient Care and Clinical Practice: This article examines the trials that led to lofexidine's new FDA-approved indication as well as other recent literature published since its last major review, seeking to guide providers in the appropriate use of lofexidine for its new indication.

CONCLUSIONS

Lofexidine is an effective and safe agent in treating symptoms related to opioid withdrawal in adults when compared with placebo; although it is more widely accessible than other first-line therapies, its use in practice may be limited by cost.

Для цитирования: Doughty Bennett, Morgenson Daralyn, Brooks Tracy. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.. The Annals of pharmacotherapy. 2019. DOI: 10.1177/1060028019828954.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.